Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sumac-Cloxacillin topical gel for diabetic foot ulcer
IRCT20220310054247N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jun 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cloxacillin in diabetic foot ulcer (DFU) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Wound area and Presence or absence of wound infection. Started Jun 2022; status: completed.
02
Drugs
cloxacillin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on IRCT20220310054247N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220310054247N1.